Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
Envoy Medical reported positive 12-month data from Stage 1 of its pivotal clinical trial for the fully implanted Acclaim cochlear implant, showing CNC word recognition scores improved to 53.2% from a 15.2% baseline. The data reflects a 38 percentage point improvement with no serious adverse events reported, validating the device's safety profile and continued efficacy gains over the 6-month readout.
Key figures
- Drug Name
- Acclaim® cochlear implant
- Phase Of Trial
- Pivotal
- Sae count
- 0
- Pma target date
- Q2 2027
- Cnc score 12mo pct
- 53.2
- Improvement 6mo pp
- 24
- Improvement 12mo pp
- 38
- Stage 1 cohort size
- 10
- Cnc score baseline pct
- 15.2
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.